{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:26:27Z","timestamp":1793784387175,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cbpa.2026.102793","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:59:14Z","timestamp":1792760354000},"page":"102793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing modern glycoconjugate vaccines: From synthetic glycans to novel conjugation approaches and carrier systems"],"prefix":"10.1016","volume":"95","author":[{"given":"Vittorio","family":"Bordoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6088","authenticated-orcid":false,"given":"Roberto","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2026.102793_bib1","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.1039\/C8CS00495A","article-title":"Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification","volume":"47","author":"Berti","year":"2018","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.cbpa.2026.102793_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14760584.2019.1657012","article-title":"Glycoconjugate vaccines: current approaches towards faster vaccine design","volume":"18","author":"Micoli","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/molecules23061451","article-title":"Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends","volume":"23","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.cbpa.2026.102793_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14760584.2023.2274955","article-title":"Glycoconjugate vaccines against antimicrobial resistant pathogens","volume":"22","author":"Sorieul","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/acs.accounts.7b00106","article-title":"Advancing homogeneous antimicrobial glycoconjugate vaccines","volume":"50","author":"Adamo","year":"2017","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.cbpa.2026.102793_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.1095209","article-title":"A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b","volume":"305","author":"Verez-Bencomo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2026.102793_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-023-00624-y","article-title":"A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults","volume":"8","author":"Meron-Sudai","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2020.09.002","article-title":"Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-\u03b2-(1\u21926)-N-acetyl-d-glucosamine exopolysaccharide","volume":"35\u201336","author":"Gening","year":"2020","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.cbpa.2026.102793_sref10","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/s41467-024-47457-4","article-title":"A comprehensive synthetic library of poly-N-acetyl glucosamines enabled vaccine against lethal challenges of Staphylococcus aureus","volume":"15","author":"Tan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102793_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202511378","article-title":"Synthesis, conformal analysis, and antibody binding of Staphylococcus aureus capsular polysaccharide type 5 oligosaccharides","volume":"64","author":"\u00d8sterlid","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2026.102793_sref12","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/jacs.4c16118","article-title":"Long, synthetic Staphylococcus aureus type 8 capsular oligosaccharides reveal structural epitopes for effective immune recognition","volume":"147","author":"\u00d8sterlid","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102793_bib13","doi-asserted-by":"crossref","first-page":"35356","DOI":"10.1021\/jacs.4c13972","article-title":"Semisynthetic glycoconjugate vaccine lead against Klebsiella pneumoniae serotype O2afg induces functional antibodies and reduces the burden of acute pneumonia","volume":"146","author":"Shen","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102793_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/acscentsci.4c00387","article-title":"A semisynthetic oligomannuronic acid-based glycoconjugate vaccine against Pseudomonas aeruginosa","volume":"10","author":"Zhang","year":"2024","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.cbpa.2026.102793_bib15","first-page":"2216","article-title":"Synthesis and immunological evaluation of Pel-derived glycoconjugate vaccine candidates against Pseudomonas aeruginosa","volume":"6","author":"Wu","year":"2026","journal-title":"J Am Chem Soc Au"},{"key":"10.1016\/j.cbpa.2026.102793_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202416432","article-title":"A synthetic oligosaccharide resembling Francisella tularensis strain 15 O-Antigen capsular polysaccharide as a lead for Tularemia diagnostics and therapeutics","volume":"64","author":"Pradhan","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2026.102793_bib17","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Synthesis of Campylobacter jejuni capsular oligosaccharides and identification of a potential O-antigen against campylobacteriosis","volume":"11","author":"Wang","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.cbpa.2026.102793_bib18","doi-asserted-by":"crossref","first-page":"25969","DOI":"10.1021\/jacs.5c08663","article-title":"Automated glycan assembly of Porphyromonas gingivalis lipopolysaccharide epitopes for vaccine design","volume":"147","author":"Omoregbee-Leichnitz","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102793_sref19","doi-asserted-by":"crossref","first-page":"15366","DOI":"10.1021\/jacs.4c03179","article-title":"A fluorinated sialic acid vaccine lead against meningitis B and C","volume":"146","author":"Jordan","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102793_bib20","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.1021\/acscatal.5c02125","article-title":"Chemoenzymatic synthesis and immunological evaluation of type Ia and Ib capsular oligosaccharides of Group B Streptococcus","volume":"15","author":"Sun","year":"2025","journal-title":"ACS Catal"},{"key":"10.1016\/j.cbpa.2026.102793_bib21","article-title":"Modeling 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) chemistry to design glycoconjugate vaccines with desired structural and immunological characteristics","volume":"12","author":"Nappini","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cbpa.2026.102793_bib22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1021\/acs.bioconjchem.0c00423","article-title":"Expanding the scope of Ugi multicomponent bioconjugation to produce pneumococcal multivalent glycoconjugates as vaccine vandidates","volume":"31","author":"Humpierre","year":"2020","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.cbpa.2026.102793_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s42004-025-01827-1","article-title":"Creating unimolecular multivalent diversity in protein conjugates via the Passerini multicomponent bioconjugation with isocyanoproteins","volume":"9","author":"Humpierre","year":"2026","journal-title":"Commun Chem"},{"key":"10.1016\/j.cbpa.2026.102793_bib24","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2021.03.070","article-title":"Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)","volume":"39","author":"Fairman","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2026.102793_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IM9.0000000000000044","article-title":"Site-specific conjugation of cell wall polyrhamnose to protein SpyAD envisioning a safe universal Group A streptococcal vaccine","volume":"3","author":"Gao","year":"2021","journal-title":"Infect Microb Dise"},{"key":"10.1016\/j.cbpa.2026.102793_bib26","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1039\/D1SC01928G","article-title":"Retaining the structural integrity of disulfide bonds in diphtheria toxoid carrier protein is crucial for the effectiveness of glycoconjugate vaccine candidates","volume":"13","author":"Carboni","year":"2022","journal-title":"Chem Sci"},{"key":"10.1016\/j.cbpa.2026.102793_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2026.125250","article-title":"Immune responses to glycoconjugate vaccines rely on a balance between polysaccharide length and glycosylation density","volume":"382","author":"Carboni","year":"2026","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.cbpa.2026.102793_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1039\/D5CB00320B","article-title":"Double-hit approach for novel glycoconjugates combining cytoplasmic glycoengineering and selective chemistry","volume":"7","author":"Palmieri","year":"2026","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102793_bib29","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1039\/D4SC08622H","article-title":"Multimeric, multivalent fusion carrier proteins for site-selective glycoconjugate vaccines simultaneously targeting Staphylococcus aureus and Pseudomonas aeruginosa","volume":"16","author":"Sorieul","year":"2025","journal-title":"Chem Sci"},{"key":"10.1016\/j.cbpa.2026.102793_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines13070703","article-title":"Recent advances in bioconjugate vaccine development","volume":"13","author":"Wren","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cbpa.2026.102793_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cbpa.2026.102793_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/vaccines10020212","article-title":"The ongoing journey of a Shigella bioconjugate vaccine","volume":"10","author":"Martin","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib33","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/infdis\/jiaf600","article-title":"Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: a first-in-human phase I\/II randomized and controlled study","volume":"233","author":"Alaimo","year":"2026","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag162","article-title":"Safety, efficacy, and immunogenicity of a multivalent adjuvanted S. aureus vaccine in adults with recent skin and soft tissue infections: an observer-blind, randomized, placebo-controlled, multinational phase 1\/2 trial","author":"Athan","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad417","article-title":"Safety, reactogenicity, immunogenicity, and dose selection of 10-valent extraintestinal pathogenic Escherichia coli bioconjugate vaccine (VAC52416) in adults aged 60-85 years in a aandomized, multicenter, interventional, First-in-Human, phase 1\/2a study","volume":"10","author":"Fierro","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1085887","article-title":"A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice","volume":"10","author":"Williams","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.cbpa.2026.102793_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1751-7915.13770","article-title":"Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice","volume":"15","author":"Li","year":"2022","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102793_sref38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-025-01068-2","article-title":"Recombinant production platform for Group A Streptococcus glycoconjugate vaccines","volume":"10","author":"Ajay Castro","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib39","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1021\/acsinfecdis.1c00415","article-title":"Development and immunogenicity of a prototype multivalent Group B Streptococcubioconjugate vaccine","volume":"7","author":"Duke","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib40","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.vaccine.2024.02.001","article-title":"Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: a phase 1 randomized controlled trial","volume":"42","author":"Borys","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2026.102793_bib41","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2026.102793_sref42","first-page":"e00807","article-title":"Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins","volume":"0","author":"Amin","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.cbpa.2026.102793_bib43","first-page":"1170","article-title":"Testing a recombinant form of Tetanus Toxoid as a carrier protein for glycoconjugate vaccines","volume":"11","author":"Oldrini","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cbpa.2026.102793_bib44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/vaccines12111290","article-title":"Nanoparticles as delivery systems for antigenic saccharides: from conjugation chemistry to vaccine design","volume":"12","author":"Archambault","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cbpa.2026.102793_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40259-023-00627-0","article-title":"Outer membrane vesicle vaccine platforms","volume":"38","author":"Micoli","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.cbpa.2026.102793_bib46","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1093\/infdis\/jiae273","article-title":"Safety and immunogenicity of a 4-component Generalized Modules for Membrane Antigens Shigella vaccine in healthy european adults: randomized, phase 1\/2 study","volume":"230","author":"Leroux-Roels","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib47","article-title":"Development of a promising bivalent vaccine against Klebsiella pneumoniae based on glycoengineered GMMA (geGMMA)","volume":"5","author":"Ye","year":"2025","journal-title":"Explorations"},{"key":"10.1016\/j.cbpa.2026.102793_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12934-024-02640-6","article-title":"Salmonella Typhimurium derived OMV nanoparticle displaying mixed heterologous O-antigens confers immunogenicity and protection against STEC infections in mice","volume":"24","author":"Bian","year":"2025","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.cbpa.2026.102793_bib49","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/vaccines10071034","article-title":"GMMA as an alternative carrier for a glycoconjugate vaccine against Group A Streptococcus","volume":"10","author":"Palmieri","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_sref50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/nano14080728","article-title":"Efficient Production of self-assembled bioconjugate nanovaccines against Klebsiella pneumoniae O2 serotype in engineered Escherichia coli","volume":"14","author":"Zhang","year":"2024","journal-title":"Nanomaterials"},{"key":"10.1016\/j.cbpa.2026.102793_bib51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41541-023-00744-5","article-title":"Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Q\u03b2 virus-like particles","volume":"8","author":"Carboni","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-024-00808-0","article-title":"Author Correction: proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Q\u03b2 virus-like particles","volume":"9","author":"Carboni","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib53","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1021\/acsinfecdis.1c00585","article-title":"Virus-like particle display of Vibrio cholerae O-specific polysaccharide as a potential vaccine against Cholera","volume":"8","author":"Rashidijahanabad","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib54","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s12274-021-3713-4","article-title":"Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection","volume":"15","author":"Li","year":"2022","journal-title":"Nano Res"},{"key":"10.1016\/j.cbpa.2026.102793_bib55","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/ijms25073736","article-title":"Impact of protein nanoparticle shape on the immunogenicity of antimicrobial glycoconjugate vaccines","volume":"25","author":"Dolce","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cbpa.2026.102793_bib56","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1021\/acsinfecdis.5c00260","article-title":"Development of a promising ferritin-based bioconjugate nanovaccine candidate against Brucellosis","volume":"11","author":"Li","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102793_bib57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-020-00229-9","article-title":"Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei","volume":"5","author":"Tapia","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.cbpa.2026.102793_bib58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejpb.2020.05.023","article-title":"Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles","volume":"152","author":"Meena","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.cbpa.2026.102793_bib59","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s42003-024-06806-1","article-title":"An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae","volume":"7","author":"Wei","year":"2024","journal-title":"Commun Biol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126001420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126001420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:32:01Z","timestamp":1793781121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593126001420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"alternative-id":["S1367593126001420"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102793","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing modern glycoconjugate vaccines: From synthetic glycans to novel conjugation approaches and carrier systems","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102793"}}